3.1. Patients characteristics
CAD
ADVERSE EVENTS, CORONARY ARTERY DISEASE, CAD
A total of 406 patients were screened, of whom 290 were randomized to one of the 4 treatment groups: A5E (n = 72), E (n = 74), A5 (n = 73), or A10 (n = 71). The first patient was enrolled in November 2021, and the last patient was enrolled in March 2022. All patients received at least one dose of the study drug. A total of 277 patients (95.5%) completed the study while 13 (4.5%) discontinued; 9 (3.1%) withdrew consent, 2 (0.7%) experienced adverse events, and 2 (0.7%) discontinued for other reasons (Fig. Baseline characteristics.CAD = coronary artery disease, SD = standard deviation.Study flow diagram.